Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s Disease

Published

Nov 4, 2020 8:15am EST

Alzheimer’s Patients Treated with Sumifilam Showed a Statistically Significant (p

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story
FLNA

Market Makers
Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.

Thanks for submitting!

Investor Relations

Contact

Careers

Advertise

Mobile Apps

Nasdaq MarketSIte

Trust Center

Newsletters

Accessibility

Privacy Policy

Cookies

Legal

Do Not Sell or Share My Personal Information

© 2026, Nasdaq, Inc. All Rights Reserved.

My Quotes

My European Quotes

Watchlist

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ETFs and more asset classes.

/

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Shares, Indexes, ETP and more asset classes.

/

Edit Watchlist

Your Watchlist is empty.

Create your Watchlist to save your favorite quotes on Nasdaq.com. Log in or create a free account to get started.

/

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy

We couldn’t find any results matching your search.

We’re sorry, we are currently experiencing some issues, please try again later.

Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s Disease

In This Story